Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03CPM
|
|||
| Former ID |
DIB001555
|
|||
| Drug Name |
SLV-334
|
|||
| Indication | Brain injury [ICD-11: NA07.Z] | Phase 2 | [1] | |
| Company |
Solvay SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H36N2O6
|
|||
| Canonical SMILES |
C1CCC(C1)(CC(CCC2=CC=CC3=CC=CC=C32)C(=O)O)C(=O)NC4CCC5=CC=CC=C5N(C4=O)CC(=O)O
|
|||
| InChI |
1S/C33H36N2O6/c36-29(37)21-35-28-13-4-2-9-24(28)16-17-27(30(35)38)34-32(41)33(18-5-6-19-33)20-25(31(39)40)15-14-23-11-7-10-22-8-1-3-12-26(22)23/h1-4,7-13,25,27H,5-6,14-21H2,(H,34,41)(H,36,37)(H,39,40)/t25-,27+/m1/s1
|
|||
| InChIKey |
LOFDNSDPZTVIIO-VPUSJEBWSA-N
|
|||
| CAS Number |
CAS 182821-33-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin-converting enzyme (ECE) | Target Info | Modulator | [2] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [2] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. | |||
| REF 2 | Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.